AzTrials
AzTrials

Staphylococcus AureusPhase 4DECO-SSINCT03962907

Preoperative Decolonization and Surgical Site Infections in Orthopaedic Surgery - 2 Year Outcome in Prosthetic Surgery

A Phase 4 study testing Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun and BACTROBAN® Nasal ong in people with Staphylococcus Aureus and Orthopaedic Surgery, run by Lindenhofgruppe AG at 1 site in Switzerland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Surgical site infections in orthopaedic surgery are a major problem. Decolonization has been suggested to reduce infection rates. The study was designed as a prospective, controlled, randomized, single-blinded trial to assess the influence of a decolonization procedure in S. aureus and non - S. aureus carriers. Read more about this study

Who is it for?
Ages 16 years and older
What is being tested?
Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun and BACTROBAN® Nasal ong
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,318 participants
Where
1 siteSwitzerland
Study dates
1 Jan 2019to 30 Jun 2020
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • older than 16 years
  • planned elective orthopedic procedure
  • Decolonization protocol can be performed timely

Who cannot join

  • No orthopedic prosthetic surgery planned
  • Allergy to mupirocin or chlorhexidine
  • Presence of a nasal foreign body
  • No informed consent
  • undergoing treatment/surgery for a documented infection
  • already participating in the study

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • Sonnenhofspital, Lindenhofgruppe

    Bern, 3006

Other trials in Switzerland

About this study

Official title: Preoperative Decolonization and Surgical Site Infections in Orthopaedic Surgery: a Prospective Randomized Controlled Trial - 2 Year Outcome in Prosthetic Surgery

Surgical site infections in orthopaedic surgery are a major problem. Decolonization has been suggested to reduce infection rates. The study was designed as a prospective, controlled, randomized, single-blinded trial to assess the influence of a decolonization procedure in S. aureus and non - S. aureus carriers. In this trial the 2 - year outcome in the subpopulation of prosthetic elective orthopaedic surgery will be evaluated.

Read the detailed description

To verify the main hypothesis, a prospective controlled randomized interventional trial with 2 parallel groups of patients of the Sonnenhof hospital undergoing an elective knee- or hip implant surgery was designed. A superiority framework for the decolonization procedure was used. All patients planned for such a procedure will be recruited during preoperative consultation by the orthopedic surgeons or by post and phone. Written informed consent will be obtained at this occasion. Study participants were screened 2-4 weeks prior intervention for nasal S. aureus colonization.

Study participants were allocated on a 1:1 basis either to an intervention or to a control group, but prosthesis implantation was not defined as randomization criteria in the initial trial. Randomization was stratified for important risk factors of SSI; procedure type (upper extremities and pelvic/hip, spine, knee and foot) and ASA-criteria (I, II, III -V). Stratification-groups were chosen in function of SSI's rate and expected number of operations/year. Randomization list were generated by the CTU and allocation was concealed using central randomization that was implemented in the REDCap data entry system.

One week prior to hospitalization patients in the intervention group received a decolonization kit by mail with instructions to apply mupirocin ointment 2% (BACTROBAN Nasal ong 3g, GSK) in each nostril 30mg (which corresponds approximately the same amount as the volume of a pea) twice a day and to shower daily (starting with the face, then from top to bottom the whole body emphasizing especially on nose, axillaries and pelvic region and then rinse. In a second time starting with the hair and then repeat the whole body. Dry with a proper towel (one for the 5 days)) with 25ml chlorhexidine gluconate soap, (Lifo-Scrub sol 4 % 500ml, B. Braun) during 5 days prior surgery. For non S. aureus carriers only skin cleansing without intranasal mupirocin application was used. This dosing schedule, mode of administration and treatment periods correspond to the allowed and recommended standards of Swissmedic and were not modified in this trial. Decolonization occured before hospitalization, as a fully completed course before surgery has been more effective. In some of the previous trials decolonization took place only at the beginning of hospitalization. The decolonization procedure was only completed after surgery had taken place and this possibly affected the results.

For practical reasons the use of a placebo kit within the control group abandoned. Operators, who are also the outcome assessors, will be blinded for either the carrier status or the decolonization procedure. Study participants will be told not to inform surgeons about performed decolonization procedure.

The incidence of PJI at two years in the intervention and control group will be assessed by phone interview.

Being tested
Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun, BACTROBAN® Nasal ong
Medical subject headings
Staphylococcal Infections, Surgical Wound Infection

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. BraunDrug

    5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.

  • BACTROBAN® Nasal ongDrug

    Mupirocin, BACTROBAN® Nasal ong, 3g, GSK

Study groups in NCT03962907
Study groupRoleWhat they receive
Carrier group - interventionExperimentalBACTROBAN® Nasal ong, 3g, GSK Lifo-Scrub sol 4%®, 500ml, B. Braun
Receives: Drug: Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun; Drug: BACTROBAN® Nasal ong
Carrier group - controlNo interventionNot described
Non - carrier group - interventionExperimentalLifo-Scrub sol 4%®, 500ml, B. Braun
Receives: Drug: Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun
Non - carrier group - controlNo interventionNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Surgical site infections

    according CDC-Criteria

    Measured: 2 years

Secondary outcomes (4)
  1. Overall mortality

    Measured: 2 years

  2. Death related to infection

    Measured: 2 years

  3. Documented bacteria

    of PJI

    Measured: 2 years

  4. Time to PJI and death

    counting from operation date

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 May 2019
  2. Study start1 Jan 2019
  3. Primary completion30 Mar 2020
  4. Study completion30 Jun 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
two groups: S. aureus carrier and non-carriers. Both groups have an intervention and control arm
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
1,318 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03962907
Sponsor's protocol ID
DECO-SSI P 2
Acronym
DECO-SSI
Status last verified
Oct 2019
First submitted
22 May 2019
Last updated
17 Jul 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun and BACTROBAN® Nasal ong in people with Staphylococcus Aureus and Orthopaedic Surgery, run by Lindenhofgruppe AG at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Surgical site infections (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in